Nanotechnology Now - Press Release: "Roche Leads Biotechnology Industry With An Unprecedented Growth Of Nearly 100%, While Geron, Nanosphere And Ultra Biotech Jump Into The Top 10 Patent"

Home > Press > Roche Leads Biotechnology Industry With An Unprecedented Growth Of Nearly 100%, While Geron, Nanosphere And Ultra Biotech Jump Into The Top 10 Patent

Abstract:
According to The Patent Board's Biotechnology Patent Scorecard published in The Wall Street Journal, Roche's top billing is due to their ownership in Genentech.

Roche Holding Ltd remains the leader for the Biotechnology Scorecard, with an unprecedented Science Strength (SS) that grew by almost 100% this past quarter. Their lead is primarily due to majority owned subsidiary and biotech, Genentech, who account for approximately 80% of the patents represented. Geron Corp, known for stem cell research has soared into the top 10 moving up 7 spots to sit in 5th position with an increase in SS™ of 77%. There are two other newcomers to the top 10, one of which is Nanosphere Inc, who is bringing the combination of nanotechnology and molecular diagnostics into the marketplace. The other is little known Ultra Biotech Ltd which utilizes electromagnetic energy for culturing biotechnology compositions.

Eight of the top 10 companies have above average Research Intensity (RI), which measures the degree of scientific referencing for their most recent patenting compared to others in the industry. The largest increases in Research Intensity™ this quarter came from 1st and 2nd ranked, Roche (52%) and Invitrogen (23%), while newcomers Geron and Nanosphere have the highest scores among the top 10 of 3.43 and 3.29 respectively. They are both referencing well known publications such as Proceedings of the National Academy of Science and The Journal of Biological Chemistry; however Nanosphere is also highly referencing the interdisciplinary journal, Langmuir, further showing its differentiation in the marketplace. Another company who is highly referencing Langmuir is Affymetrix, ranked 18th (not charted) who pioneered the use of semiconductors and combinatorial chemistry for biotechnology use. Despite dropping a spot each this quarter, both Isis Pharmaceuticals Inc and Biogen Idec Inc have RI scores twice the industry average.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark: